Woodford Equity Income Fund

The Woodford Equity Income Fund was a prominent UK-based investment fund managed by Neil Woodford through Woodford Investment Management. Launched in 2014, the fund became notable for its significant allocations to early-stage, unquoted life science and biotechnology companies, diverging from traditional equity income strategies. Following a period of poor performance and high redemption requests, the fund was suspended in June 2019 and subsequently entered a liquidation process. Its portfolio included major stakes in healthcare innovators such as Oxford Nanopore Technologies, BenevolentAI, and Kymab. The fund's collapse led to significant regulatory scrutiny and remains a landmark event in the UK financial services industry.